



HPV Vaccination Programs

Cross-country learning and best practices.

HPV Vaccination Program in China

Prof. Youlin Qiao

School of Population Medicine and Public Health,
Chinese Academy of Medical Sciences &
Peking Union Medical College, Beijing, China



COALITION to STRENGTHEN
the HPV IMMUNIZATION
COMMUNITY

Recent Advances in HPV Vaccines in China

- **China approves first domestically produced nine-valent HPV vaccine**
 - On **June 4, 2025**, first domestically produced nine-valent HPV vaccine “**Cecolin-9**” had been officially approved for market authorization in China.
- **HPV vaccine approved for male use in China**
 - On **January 8, 2025**, MSD quadrivalent HPV vaccine was allowed it to be used for males aged 9 to 26.
 - On **April 14, 2025**, MSD further announced that its nine-valent HPV vaccine, Gardasil-9, had received regulatory approval in China for an expanded indication in males, available for males aged 16 to 26.

Vaccine Type & Name	Quadrivalent Gardasil	Bivalent Cervarix	9-valent Gardasil-9	Domestic Bivalent Cecolin	Domestic Bivalent Walvax	Domestic 9-valent Cecolin-9
Manufacturer	Merck & Co., USA	GSK, UK	Merck & Co., USA	Xiamen Innovax, China	Walvax, China	Xiamen Innovax, China
Global Market Launch	2006	2007	2014	WHO PQ 2021	WHO PQ 2024	Expected 2025
China Market Launch	2017	2016	2018	2019	2022	2025
HPV Types Prevented	6 / 11 / 16 / 18	16 / 18	6 / 11 / 16 / 18 / 31 / 33 / 45 / 52 / 58	16 / 18	16 / 18	6 / 11 / 16 / 18 / 31 / 33 / 45 / 52 / 58
Approved Age Range in China	Females 9–45 yrs Males 9–26 yrs	Females 9–45 yrs	Females 9–45 yrs Males 16–26 yrs	Females 9–45 yrs	Females 9–30 yrs	Females 9–45 yrs

Update of HPV vaccination programme coverage in China

- Up to May 2025,
 - **25 pilot cities** have adopted free or fixed financial compensation policies for the HPV vaccination
 - **18 Provinces and more than 30 regions** have launched the regional HPV vaccination for free or subsidized vaccination policies
- Population coverage
 - The total population of 18 provinces accounts for both gender **58.68%** and for female **59.02%** of the national population.
- Looking forward:
 - From pilot projects to NIP by end of October 1, 2025.

